ACTRN12605000731695尚未招募2 期
Phase II study of the addition of darbepoetin alfa (Aranesp) and pegfilgrastim (Neulasta) support for optimal dose-dense chemotherapy for early breast cancer
Mater Adult hospital0 个研究点目标入组 30 人开始时间: 2005年11月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- Female
入选标准
- •Histologically confirmed operable stage IIA, IIB, or IIIA adenocarcinoma of the breast.No prior treatment other than surgery is permitted.
排除标准
- •No exclusion criteria
研究者
相似试验
已完成
不适用
The effect of intervention with darbepoetin alfa on progression of renal decline[chronic renal failure?] in renal anaemia patients with chronic kidney disease not on dialysis.renal anaemia patients with chronic kidney disease not on dialysisJPRN-UMIN000006963Division of Nephrology,Department of Internal Medicine,Juntendo University Faculty of Medicine200
已完成
不适用
Analysis on response to darbepoetin alfa in patients with low risk myelodysplastic syndromesJPRN-UMIN000022185Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu85
进行中（未招募）
不适用
Evaluation of the Efficacy of Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelodysplastic Syndrome - DARB-MDSEUCTR2005-004737-17-ITAZIENDA OSPEDALIERA BIANCHI-MELACRINO-MORELLI54
已完成
3 期
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)MDSNCT01362140Amgen147
已完成
不适用
ong-term usage of darbepoetin alpha in non-dialysis CKD patientson-dialysis CKDJPRN-UMIN000017252Kyowa Hakko Kirin Co., Ltd.3,000